Clinical Trial Update: ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial update describing ResQ1010 combined with chemoimmunotherapy versus chemoimmunotherapy alone as first-line treatment for advanced/metastatic non-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ResQ1010

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | Phase 3 | Status: NOT_YET_RECRUITING